Sun Pharma receives USFDA nod for anti-cancer injection
New Delhi: Sun Pharmaceutical Industries today said it has received US health regulator`s approval to market generic version of Doxil injection, used in treating ovarian cancer in the American market.
The Mumbai-headquartered firm, in a statement, said its subsidiary has received approval from US food and Drug Administration (USFDA) for its Doxorubicin HCl Liposome Injection.
"This generic Doxorubicin HCl Liposome injection USP, 2 mg/ml is therapeutically equivalent to Doxil Liposome Injection, 2 mg/ml of Janssen Research and Development, LLC," the company said.
Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.
Reacting to the development, shares of Sun Pharma were trading at Rs 745.70 on the BSE in afternoon trade, up 3.84 per cent from their previous close.
More from India
More from World
More from Sports
More from Entertaiment
- APJ Abdul Kalam's funeral to be held in Rameswaram; PM Modi to attend
- Yakub Memon hanged in Nagpur jail: As it happened
- Yakub Memon's body handed over to family, tight security in Mumbai
- Yakub Memon wanted to meet his daughter before being hanged
- It's a canard that Kalam was reluctant to appoint Sonia Gandhi as PM: Manmohan Singh